DU
VRTX icon

Delphia (USA)’s Vertex Pharmaceuticals VRTX Stock Holding History

Delphia (USA)’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,021
Closed -$359K – 189
2023
Q2 		$359K Sell
1,021
-471
-32% -$159K 0.57% 57
2023
Q1 		$470K Buy
1,492
+757
+103% +$227K 0.58% 43
2022
Q4 		$212K Buy
+735
New +$224K 0.24% 187
2022
Q3 		– Sell
-1,667
Closed -$470K – 426
2022
Q2 		$470K Sell
1,667
-411
-20% -$110K 0.32% 96
2022
Q1 		$542K Buy
2,078
+7
+0.3% +$1.66K 0.41% 68
2021
Q4 		$455K Buy
+2,071
New +$403K 0.48% 51

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Delphia (USA)'s VRTX Position: Q3 2023 in Review

Delphia (USA) sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 1,021 shares — an estimated $359K sold.

Delphia (USA) first reported a position in VRTX in Q4 2021 and held it in 6 quarters. The position peaked at $542K in Q1 2022. 1,278 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

  • Delphia (USA) reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Delphia (USA) sold 1,021 Vertex Pharmaceuticals shares in Q3 2023, an estimated $359K.
  • Delphia (USA) first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 6 quarters.
  • Delphia (USA)'s Vertex Pharmaceuticals position peaked at $542K in Q1 2022.
  • 1,278 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Delphia (USA)'s 13F filing for Q3 2023, filed 15 Nov 2023.